Zentiva
Petr Charamza has a diverse work experience in the pharmaceutical industry. Petr started working at Zentiva in 2009 as a Portfolio Building specialist and continued in various roles until 2017. At Sanofi, they served as a Pricing Manager before being promoted to Global Senior Pricing & Market Access Manager at the Generics Division. From 2016 to 2017, Petr was the Global Pricing Lead for Lantus & Biosimilars. After returning to Zentiva in 2017, they assumed the positions of Head of Pricing & Market Intelligence and Head of Corporate Development Strategy.
Petr Charamza completed their Bachelor's degree in Economic Theories at Charles University from 2004 to 2006. Petr then pursued a Master's degree in Finance and Banking from Charles University from 2006 to 2009. In 2008, they attended NEOMA Business School to further their studies in Finance.
This person is not in any offices
Zentiva
5 followers
Zentiva is a Pan-European Platform developing, manufacturing and providing high-quality and affordable medicines to more than 100 million people in Europe. Zentiva has 4 wholly owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. We offer solutions in key therapeutical areas like Cardiology & Circulation, Diabetes, Oncology, Respiratory, CNS and focus on expanding our portfolio in self-care. The company is Private Equity owned, delivering sustainable double-digit growth, with an ambitious 5-year plan for further strong (organic and inorganic) growth across Europe. We are a team of almost 5,000 unique talents bonded together by our mission to deliver high-quality and affordable medicines to people who depend on them every day. We want Zentiva to be a great place to work, where everyone feels welcomed and appreciated and can be their true selves contributing to the best of their ability.